Evidence map›Paper›PMID 40588678›Full record

ArticleAnnals of nuclear medicine2025

Prognostic value of pre-treatment metabolic tumor volume on [S‑methyl‑

Kentaro Tamura, Ryuichi Nishii, Atsushi B Tsuji, Jitsuro Tsukada, Takamasa Maeda, Mio Nakajima, Shigeru Yamada, Hitoshi Ishikawa, Kana Yamazaki, Tatsuya Higashi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Tumor Characterization Using [Pharmaceuticals (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kentaro TamuraDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Ryuichi NishiiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Atsushi B TsujiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Jitsuro TsukadaDepartment of Diagnostic Radiology, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Takamasa MaedaDepartment of Medical Technology, QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Mio NakajimaDepartment of Diagnostic Radiology and Radiation Oncology, QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Shigeru YamadaDepartment of Diagnostic Radiology and Radiation Oncology, QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Hitoshi IshikawaDepartment of Diagnostic Radiology and Radiation Oncology, QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Kana YamazakiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan. tatsuya.higashi@qst.go.jp.ORCID http://orcid.org/0000-0002-8338-4737
Masahiro JinzakiDepartment of Diagnostic Radiology, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the prognostic predictive ability of MET PET/CT-derived imaging biomarkers in patients with localized non-small cell lung cancer (NSCLC) undergoing single-fraction carbon-ion radiotherapy (CIRT) and to clarify the additional prognostic information these biomarkers can provide beyond the standard UICC staging protocol.

methodsWith institutional review board approval, 67 localized NSCLC patients eligible for CIRT between 2007 and 2012 were included. Single-fraction doses of 40-50 Gy were irradiated. MET PET imaging using the Toshiba Aquiduo or Siemens Biograph 16 commenced 20 min post 740 MBq MET injection before CIRT. Experienced radiologists analyzed the images, defining metabolic tumor volume (MTV) as areas with SUV > 1.5. Statistical analysis was performed using SPSS 29, including Cox proportional hazard models for disease-free and overall survival.

resultsSeven cases with Tis of T stage were excluded because of low MET radiotracer uptake. A total of 60 patients were analyzed: 36 males and 24 females with a mean age of 73 years; 35 cases of T1, 24 cases of T2, and one T3 case. The average follow-up period was 74.3 months. The univariate Cox proportional hazard analyses showed that SUVmax, MTV, and total lesion retention (TLR) correlated with disease-free survival (DFS), while no significant difference was noted in treatment dose. For overall survival (OS), solid tumor diameter, SUVmax, MTV, TLR, and sex showed significant correlations in the univariate analysis. The multivariate analysis identified MTV as the only significant prognostic factor for both DFS and OS. Kaplan-Meier survival curves further supported these findings, with log-rank tests indicating a significant difference in survival duration related to MTV in both DFS and OS.

conclusionMTV in pre-treatment MET PET/CT would be a valuable predictor of DFS and OS of localized NSCLC treated with single-fraction CIRT.

Indexed as

Carcinoma, Non-Small-Cell LungHeavy Ion RadiotherapyLung NeoplasmsMethioninePositron Emission Tomography Computed TomographyTumor BurdenAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesMethionineAmino acid PET/CTMetabolic tumor volumeMethionine PET/CTNon-small cell lung cancer

Identifiers

PMID40588678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.